Zydus Lifesciences settles patent dispute with Astellas Pharma for 120 million dollars
Zydus Lifesciences will pay 120 million dollars to Astellas Pharma to settle a patent dispute. The deal includes licensing fees on U.S. sales through September 2027.
Insights:
Zydus Lifesciences and its unit in the United States 
US have agreed to pay $120 million to Astellas Pharma Inc. to settle a patent dispute regarding the drug Mirabegron. Announced on February 12, 2026, the agreement establishes a new commercial framework for generic Mirabegron sales in the United States. Under the terms of the settlement, the India 
IN-based Zydus Lifesciences and its American subsidiary will also provide a pre-paid per-unit licensing fee on all U.S. sales of the generic medication through September 2027.
US have agreed to pay $120 million to Astellas Pharma Inc. to settle a patent dispute regarding the drug Mirabegron. Announced on February 12, 2026, the agreement establishes a new commercial framework for generic Mirabegron sales in the United States. Under the terms of the settlement, the India IN-based Zydus Lifesciences and its American subsidiary will also provide a pre-paid per-unit licensing fee on all U.S. sales of the generic medication through September 2027.
